07:00 , Jul 6, 1999 |  BC Week In Review  |  Company News

Cytel, Epimmune deal

The companies completed their previously announced merger (see BioCentury, June 21). The merged company, Epimmune Inc., will trade on NASDAQ under the symbol EPMN. Cytel Corp. (CYTL), San Diego, Calif.   Epimmune Inc., San Diego,...
07:00 , Jul 6, 1999 |  BioCentury  |  Finance

Fair to middling

The BioCentury 100 gained 7 percent in the second quarter, but was outpaced by the Dow Jones Industrials and the NASDAQ Composite, which gained 12 percent and 9 percent, respectively. Notably, the laggard of the...
07:00 , Jun 21, 1999 |  BC Week In Review  |  Company News

Cytel, Epimmune infectious diseases, cancer news

CYTL will merge with its Epimmune majority-owned subsidiary and change its name to Epimmune Inc. (see BioCentury, April 5). After completion of the merger, expected on June 30, the company will trade on NASDAQ under...
07:00 , May 17, 1999 |  BC Week In Review  |  Company News

Cytel other research news

CYTL's Epimmune Inc. subsidiary received a five-year $2.25 million grant from the National Institute of Allergy and Infectious Diseases to develop epitope-based vaccines using Epimmune's EIS, which allows for identification and validation of T...
07:00 , May 3, 1999 |  BC Week In Review  |  Company News

Cytel management update

Cytel Corp. (CYTL), San Diego, Calif.   Business: Infectious diseases   Resigned: Virgil Thompson as president and CEO to become president and COO of Bio-Technology General Corp. while remaining a CYTL director   Transition: Robert Roe becomes...
07:00 , May 3, 1999 |  BC Week In Review  |  Company News

Bio-Technology General management update

Bio-Technology General Corp. (BTGC), Iselin, N.J.   Business: Cardiovascular, Metabolic, Ophthalmic   Hired: Virgil Thompson as president and COO, formerly president and CEO of Cytel Corp.; and Eli Admoni, as president of Bio-Technology General (Israel) Ltd....
07:00 , Apr 12, 1999 |  BC Week In Review  |  Clinical News

Cytel preclinical data

Epimmune reported in the Journal of Immunology that a PADRE-based vaccine enhanced T lymphocyte function in mice chronically producing HBV. Cytel Corp. (CYTL), San Diego, Calif.   Product: Epitope-based hepatitis B virus (HBV) vaccine containing PADRE...
07:00 , Apr 12, 1999 |  BC Week In Review  |  Clinical News

Cytel preclinical data

CYTL's Epimmune subsidiary published in Vaccine that vaccination with PADRE coupled to a single B cell epitope from a malarial antigen gave high-titer, long-lasting antibody responses and protection from viral challenge in 75 percent of...
07:00 , Apr 12, 1999 |  BioCentury  |  Finance

Looking for some magic

Looking for some magic Company 3/31/98 close 3/31/99 close % chg Angiotech (TSE:ANP) C$17.250 C$13.00 -25% Biocompatibles (LSE:BII) 171.5p 107.5p -37% Cadus (KDUS) $8.312 $1.000 -88% Cell Therapeutics (CTIC) $4.125 $3.500 -15% Core Group (LSE:COG)...
07:00 , Apr 5, 1999 |  BC Week In Review  |  Clinical News

Cylexin: Phase II/III

Cylexin showed no benefit over placebo in a 138-patient Phase II/III trial. CYTL said it has halted trials of Cylexin and will end its pursuit of cell adhesion therapeutics. Cytel Corp. (CYTL), San Diego, Calif....